Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laquinimod for Huntington's disease (0.5, 1.0, 1.5 mg vs placebo)
2014-000418-75Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of laquinimod in Huntington disease (HD) (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change from baseline in UHDRS Total Motor Score at Month 12 / Early Termination. Started Aug 2014; status: completed.
02
Drugs
laquinimod
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2014-000418-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000418-75.